Referring Clinician
Please email all referrals to CentralReferrals@adhb.govt.nz (including Att: ACTC in email subject)
NOTE: referrals only accepted from oncologists/haematologists.
Email us for any other queries: infoACTC@adhb.govt.nz
| Tumour Stream | Trial Name | Study Description | Key Investigational Agent | Key Inclusion Criteria | Recruitment Status |
|---|---|---|---|---|---|
| All Cancers | Beigene SMAC mimetic BGB-24714-101 | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Smac Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced Solid Tumors | BGB-24714 (SMAC mimetic) +/- paclitaxel | • Measurable disease • ECOG PS 0-1 • Adequate organ function | Open |
| All Cancers | BGB-15025 and Tislelizumab in advanced solid tumours | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination with Anti-PD- 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors | BGB-15025 (oral HPK1 inhibitor) +/- tislelizumab | • Measurable disease • Must have biopsiable disease or archival tissue • ECOG PS 0-1 • Adequate organ function • No history of autoimmune disorders (please discuss with investigators) | Open |
| All Cancers | BGB-A317-26808-101 (HPK2) | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Ad-vanced Solid Tumors | BGB-26808 (HPK1 Inhibitor) +/- Tislelizumab | Open | |
| All Cancers | BGB-53038-101 Pan-KRAS | A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmaco-dynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | BGB-53038 (Pan-KRAS Inhibitor) | Open | |
| All Cancers | MK6482-016 | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors | Pembrolizumab + Lenvatinib + Belzutifan | Open | |
| All Cancers | TAPISTRY BO41932 | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial | • ALK – Alectinib • NTRK 1/2/3 - entrectinib • ROS – entrectinib • PIK3CA – inavolisib • RET -praseltinib (AKT, MDM2, HER2, BRAF & TMB high arms closed) | • At least 2L treatment or no acceptable treatment • Measurable disease • Must have archival tissue or biopsiable disease for NGS testing (FNA not allowed) • ECOG PS 0-1 • Adequate organ function • NSCLC not allowed for ALK/ROS arms | Open |
| All Cancers | ZION | A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients with HER2-Positive Advanced Solid Tumors | ZN-A-1041 (single agent or in combination) | Open | |
| Breast/GI | APEC | Does the Concomitant Administration of Proton Pump Inhibitors Affect Capecitabine Pharmacokinetics? – A Prospective, Single-Centre, Two-Arm, Randomised, Unblinded, Cross-Over Bioequivalence Study of Capecitabine With or Without Concomitant Pantoprazole. | Pantoprazole | • At least 2 cycles of single agent capecitabine • CAPOX not permitted. | Open |
| Gastrointestinal | CITRON | Reducing Oxaliplatin Neurotoxicity: A Phase 1B Randomized, Double-Blind, Placebo- Controlled, Crossover, Dose-Finding and Proof-of-Concept Trial of Cimetidine in Gastrointestinal Cancer Patients | Cimetidine | • At least 2 cycles of oxaliplatin-based chemotherapy • Must not have pre-existing >G1 peripheral neuropathy | Open |
| Lymphoma | BGB-11417-101 | A Phase 1/1b Open-Label Dose Escalation and Expansion Study of the Bcl-2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib (BGB-3111) in Patients With Mature B-Cell Malignancies | Open | ||
| Lymphoma | NP30179 | A multicenter, open-label, phase 1 study to evaluate the safety, efficacy, tolerability and pharmacokinetics of escalating doses of RO7082859 as a single agent and in combination with obinutuzumab administered after a fixed, single dose pre-treatment of obinutuzumab (Gazyva/Gazyvaro) in patients with relapsed/refractory B-cell non-hodgkin's lymphoma | Open | ||
| Prostate | MK-365 | Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) | Currently open – pembrolizumab + lenvatinib (both AC, NET) , pembrolizumab + carboplatin + etoposide (NET) | • Adenocarcinoma, neuroendocrine • Biopsiable disease from non-irradiated site (bone allowed for certain cohorts) • Prior anti PD1/PDL1, radiopharmaceuticals, superscan not permitted. | Open |
| Prostate | MK-5684-01A Substudy | A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) | Open | ||
| Renal | ICON Exelixis XL092-002 Stellar 002 | Phase 1b dose escalation and expansion study with our new TKI combined with Nivolumab, Nivolumab/Ipilimumab or Nivolumab/BEMPEG | Open |